We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Screening Blood Supply for Murine Viruses Is Superfluous

By LabMedica International staff writers
Posted on 11 Oct 2011
The validity of testing techniques intended to detect the presence of several viruses in blood donated for transfusion has been examined. More...


Murine leukemia viruses (MLV), including xenotropic-MLV-related virus (XMRV), and the related polytrophic murine leukemia viruses (P-MLVs) were looked for in blood samples of healthy donors who were previously known to not have the viruses.

In a recent study, blood samples were taken from healthy donors and from 14 patients with chronic fatigue syndrome (CFS) who had previously tested positive for XMRV or P-MLV, and samples from another person who had tested positive for XMRV but who did not have CFS. The study also used blood samples from healthy volunteers whose blood tests previously had shown no signs of XMRV/P-MLV. The scientists used 11 nucleic acid, five antibody, and three culture assays to determine the assays’ abilities to detect XMRV/P-MLVs. The study also checked for evidence of contamination with mouse DNA, because XMRV or its predecessors may be present in some mouse strains and cell lines. The MLV have been controversially linked to CFS.

The samples were blinded with no indication as to their source, and sent to nine laboratories. The study involved laboratories supported by several US governmental agencies along with Abbott Laboratories (Abbott Park, IL, USA), GenProbe, Inc. (San Diego, CA, USA), and the Whittemore Peterson Institute (WPI; Reno, NV, USA). The laboratories reported similar rates of finding XMRV in samples from patients with chronic fatigue syndrome and from healthy donors who were known to not have XMRV. Additional tests run in the same and other laboratories on the same samples did not find XMRV, strongly suggesting that these persons were negative for XMRV/P-MLVs. This would be a sign that the few observed positive results represented false-positives, which means the results indicated the condition was present when it actually was not.

Susan B. Shurin, MD, from the US National Institutes of Health (Bethesda, MD, USA), said, “The results of this study, along with other recent findings, reassure us that these viruses do not pose a threat to the safety of the nation’s blood supply. These data add to the mounting evidence that there is no need to screen blood donors for them at the present time.”

The report was published on September 22, 2011, in the journal Science Express.

Related Links:
Abbott Laboratories
GenProbe
US National Institutes of Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
HPV Test
Allplex HPV28 Detection
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.